METHOD AND SYSTEM FOR EVALUATING POTENTIAL DRUG COMPOSITIONS FOR TARGET DISEASE

1 . A method for evaluating potential drug compositions for a target disease, the method comprising

providing a data input to a discovery engine, the data input comprising information relating to investigational clinical drugs, approved drugs, and generic drugs;

using the discovery engine to identify a first set of potential drug compositions for the target disease, wherein the discovery engine is configured to:

analyze failed clinical assets of drugs for the target disease, wherein the discovery engine filters clinical trials which have failed due to non-drug safety related issues,

perform differential gene expression analysis on normalized target-disease-related data acquired from omics databases,

evaluate effect of known drugs used for diseases similar to the target disease, and

perform a network-based analysis to identify repurposable drugs based on similar targets and indirect pathways for the target disease;

using asset prioritization to filter the first set of potential drug compositions to determine at least one potential drug composition for the target disease; and

validating the at least one potential drug composition for the target disease based on biological evidence and differential expression analysis.

2 . A method of claim 1 , wherein analyzing the failed clinical assets of drugs comprises eliminating any active clinical trials.

3 . A method of any of claim 1 , wherein performing differential gene expression analysis on normalized target-disease-related data acquired from omics databases comprises:

collecting target-disease-related data from omics databases;

normalizing the target-disease-related data to eliminate technical errors therefrom, wherein normalization is performed using at least one of: LOWESS Normalization, quantile normalization;

performing differential gene expression analysis on the normalized target-disease-related data;

prioritizing markers identified in differential gene expression analysis using at least one of: centrality algorithms, pathway and gene function relevancy, druggability assessments, manual scientific and prioritization.

4 . A method of claim 1 , wherein evaluating effect on known drugs is carried out using at least one of

Fingerprint approach

Clinical trial adverse events approach

5 . A method of claim 1 , wherein network-based analysis is performed on a multi-entity network comprising nodes representing drugs, targets, diseases and pathways.

6 . A method of claim 1 , wherein asset prioritization to filter the first set of potential drug compositions to determine at least one potential drug composition comprises filtering based on

potential drug compositions with no active clinical trials against the target disease;

inhibitory mechanisms of the potential drug compositions;

experimental support for the effectiveness against the target disease;

adverse events reported in public domain against the potential drug composition;

overall survival reports related to the target disease; and

binding affinity of the potential drug compositions.

7 . A method of claim 1 , wherein the method comprises associating the potential drug composition with a plurality of targets using the biological evidence and the differential expression analysis to validate the at least one potential drug composition.

8 . A method of claim 1 , wherein the method comprises evaluating one or more potential drug compositions to be used in combination with each other at a specific ratio.

9 . A system for evaluating potential drug compositions for a target disease, the system comprising a processor configured to

receive a data input to a discovery engine executable by the processor, the data input comprising information relating to investigational clinical drugs, approved drugs, and generic drugs;

use the discovery engine to identify a first set of potential drug compositions for the target disease, wherein the discovery engine is configured to:

analyze failed clinical assets of drugs for the target disease, wherein the discovery engine filters clinical trials which have failed due to non-drug safety related issues,

perform differential gene expression analysis on normalized target-disease-related data acquired from omics databases,

evaluate effect of known drugs used for diseases similar to the target disease, and

perform a network-based analysis to identify repurposable drugs based on similar targets and indirect pathways for the target disease;

use asset prioritization to filter the first set of potential drug compositions to determine at least one potential drug composition for the target disease; and

validate the at least one potential drug composition for the target disease based on biological evidence and differential expression analysis.

10 . A system of claim 9 , wherein the processor is configured to analyze the failed clinical assets of drugs by eliminating any active clinical trials.

11 . A system of claim 9 , wherein the processor is configured to perform differential gene expression analysis on normalized target-disease-related data acquired from omics databases by:

collecting target-disease-related data from omics databases;

normalizing the target-disease-related data to eliminate technical errors therefrom, wherein normalization is performed using at least one of: LOWESS Normalization, quantile normalization;

performing differential gene expression analysis on the normalized target-disease-related data;

prioritizing markers identified in differential gene expression analysis using at least one of: centrality algorithms, pathway and gene function relevancy, druggability assessments, manual scientific and prioritization.

12 . A system of claim 9 , wherein the processor is configured to evaluate effect on known drugs is carried out using at least one of:

Fingerprint approach

Clinical trial adverse events approach

13 . A system of claim 9 , wherein the processor is configured to perform network-based analysis on a multi-entity network comprising nodes representing drugs, targets, diseases and pathways.

14 . A system of claim 9 , wherein the processor is configured to perform asset prioritization to filter the first set of potential drug compositions to determine at least one potential drug composition based on

potential drug compositions with no active clinical trials against the target disease;

inhibitory mechanisms of the potential drug compositions;

experimental support for the effectiveness against the target disease;

adverse events reported in public domain against the potential drug composition;

overall survival reports related to the target disease; and

binding affinity of the potential drug compositions.

15 . A system of claim 9 , wherein the processor is configured to associate the potential drug composition with a plurality of targets using the biological evidence and the differential expression analysis to validate the at least one potential drug composition.

16 . A system of claim 9 , wherein the processor is configured to evaluate one or more potential drug compositions to be used in combination with each other at a specific ratio.

17 . A pharmaceutical composition comprising an effective amount of deferasirox (DFX), one or more chemotherapeutic agents and one or more pharmaceutically acceptable excipients for the treatment of pancreatic cancer.

18 . A pharmaceutical composition of claim 17 , wherein the one or more chemotherapeutic agents effective against pancreatic cancer are at least one of: Albumin-bound paclitaxel (Abraxane), Capecitabine (Xeloda), Carboplatin (Paraplatin), Cisplatin, Cyclophosphamide (Cytoxan), Daunorubicin, Docetaxel, Doxorubicin, Epirubicin, Eribulin (Halaven), Gemcitabine (Gemzar), Irinotecan (Camptosar), Ixabepilone (Ixempra), Methotrexate, Mitomycin (chemical name: mutamycin), Mitoxantrone, Paclitaxel, Thiotepa, Vincristine and Vinorelbine (Navelbine).

19 . A pharmaceutical composition of claim 17 , wherein deferasirox (DFX) is employed in combination with gemcitabine (GEM) for the suppression of Ribonucleotide reductase (RR) activity.

20 . A pharmaceutical composition of claim 17 , wherein the treatment comprises administration of initial DFX dose of 20 mg/kg body weight of the subject.